we ranked as “Top 100 Enterprises for Technological Innovation in Zhejiang Province in 2015”.
we won the 2015 Most Powerful Brand Enterprise Award.
we were listed as an enterprise in the second batch for pilot cultivation of “three well-known programs” of Zhejiang Province.
we were awarded “Star for Internationalization in the 12th Five-Year Plan” in the pharmaceutical industry of China.
Chen Baohua, general manager of Huahai Pharmaceutical Co., Ltd., was elected as “Figures of China's Pharmaceutical Economy in 2015”.
we were granted with an approval number from the FDA of the US for our preparation Escitalopram Oxalate Tablets.
we established the EHS Management System Committee and held the first meeting.
Zhejiang Apeloa Pharmaceutical signed a framework agreement for strategic cooperation with Huahai (USA) Company.
we ranked as “Top 100 Well-known Pharmaceutical Enterprises in China”.
we ranked as “Top 10 Valuable Pharmaceutical Companies Listed in 2015”.
we were approved for clinical trials for I, II, and III of our innovative drug Hydroxypiperone Hydrochloride developed with the Academy of Military Medical Sciences.
we were listed again as “Top 100 Enterprises in the Pharmaceutical Industry of China in 2014” at the 32nd National Pharmaceutical Industry Information Conference.
we were approved by the FDA of the US for our new antidepressant drug Bupropion Hydrochloride Sustained-Release Tablets.
we were granted with an approval number from the FDA of the US for our preparation Valsartan Tablets.
Huahai (USA) Company signed a framework agreement for strategic cooperation with Shouguang Fukang Pharmaceutical Co., Ltd.
we were granted with an approval number from the FDA of the US for our preparation Levetiracetam Extended-Release Tablets.
we won the first prize of the 2014 Tianjin Science & Technology Progress Award for the program “R&D and industrialization of refining and crystallization technologies for high-end pharmaceutical products” jointly completed with Tianjin University, Shenzhen Huarun Jiuxin Pharmaceutical Co., Ltd., Xi’an Lijun Pharmaceutical Co., Ltd. and National Institutes for Food and Drug Control.
we ranked as “Top 20 Enterprises of China for Export of Western Medicine API in 2014” and “Top 20 Enterprises of China for Export of Generic Medicine in 2014”.
we ranked as “Zhejiang High-tech Enterprise in 2014”.
we increased capital to hold Huzhou Changxing Pharmaceutical CO., Ltd.
Shanghai Huaota Biopharm Co., Ltd. officially started to construct the pilot platform for the research and development of biological products.
our first program with ONCOBIOLOGICS company in the US was successfully put into trial production in Shanghai Huaota Biopharm Co., Ltd.
we cooperated with Liu Changxiao, academician of the Chinese Academy of Engineering, to build an academician workstation.
we successfully transferred the technologies for the first program “Class-1.1 new antidepressant drug Hydroxypiperone Hydrochloride Tablets” under the cooperation with Academy of Military Medical Sciences.
we set up “Research Institute for Environmental Protection and Engineering” and “Postdoctoral Workstation for Environmental Protection” with Tongji University.
our program “Development and Industrialization of Green Key Technologies for Anti-Hypertension Sartan Drugs” submitted jointly with Shanghai Institute of Pharmaceutical Industry and Changzhou Siyao Pharmaceutical Co., Ltd. won the second prize of National Science and Technology Progress Award.
our Pregabalin Capsules, the first product in the program “R&D in one place and declaration in three places”, was successfully launched in Germany.